No Data
No Data
Telix Pharma Reports Positive Data From Clinical Study of Prostate Cancer Drug; Shares Surge 15%
Telix Pharmaceuticals (ASX:TLX) reported further positive results from the ProstACT SELECT trial of TLX591 as treatment of patients with prostate-specific membrane antigen-positive metastatic castrate
Why Is the Telix Pharmaceuticals Share Price Soaring 11% Today?
The Telix Pharmaceuticals Ltd (ASX: TLX) share price is racing higher today.
Telix Announces Positive RPFS Data From ProstACT SELECT Trial of TLX591 RADC Therapy Candidate in Prostate Cancer
TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen. Reported median r
Telix Pharmaceuticals Submits New Drug Application for Prostate Cancer Imaging Agent to US FDA
Telix Pharmaceuticals (ASX:TLX) submitted a New Drug Application to the US Food and Drug Administration for TLX007-CDx, a new cold kit for the preparation of PSMA-PET imaging for prostate cancer, acco
Telix Gets Its Foot in the FDA Door Bringing Prostate Cancer Detection Closer to Neglected Americans
Telix Pharmaceuticals has submitted a new drug application to the United States Food and Drug Administration for TLX007-CDx, a new and proprietary cold kit for the preparation of PSMA-PET imaging for prostate cancer.
Telix Pharmaceuticals Ltd. (TLPPF) Gets a Buy From Wilsons
No Data